{"name":"Assembly Biosciences","slug":"assembly-biosciences","ticker":"","exchange":"","domain":"","description":"Assembly Biosciences is a clinical-stage biotechnology company focused on developing novel therapeutics for viral infections and liver diseases. The company has a robust pipeline of 26 drug candidates, with several in Phase 1 trials, and is committed to advancing treatments that address significant unmet medical needs.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":72303000,"revenueGrowth":153.5,"grossMargin":0,"rdSpend":64813000,"netIncome":-6122000,"cash":257590000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ABI-H3733 Solid Oral Dosage Form","genericName":"ABI-H3733 Solid Oral Dosage Form","slug":"abi-h3733-solid-oral-dosage-form","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ABI-H3733 Solid Oral Dosage Form","genericName":"ABI-H3733 Solid Oral Dosage Form","slug":"abi-h3733-solid-oral-dosage-form","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"date":"2026-03-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOTzB0MzlEaDd5aUxVczNOeWVybEEzRmhLRlpOWWRsZVEybVFHdW5YSUxwMk10SzBmUkpnRnI3MTdOMDJPZjN0Q0toTE1pSndmMFJTcFBXVjhweFAtTGNJWlc2aHBRd1lKUlZxTzRCUzRUYlNlSlMtOURScEFYcWZpbm1rMDhuMENxNjIxcjZYbHVSMkJMbXljU010OS11RzhXWFh0WkRaVVk?oc=5","date":"2026-03-20","type":"trial","source":"Fierce Biotech","summary":"Gilead turns down chance to build on Assembly's phase 1-stage HBV antiviral - Fierce Biotech","headline":"Gilead turns down chance to build on Assembly's phase 1-stage HBV antiviral","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-20","type":"earnings","source":"simplywall.st","summary":"Assembly Biosciences (ASMB) Quarterly Profit Of US$22.1 Million Tests Bearish Narratives - simplywall.st","headline":"Assembly Biosciences (ASMB) Quarterly Profit Of US$22.1 Million Tests Bearish Narratives","sentiment":"neutral"},{"date":"2026-03-19","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-22","type":"pipeline","source":"simplywall.st","summary":"Some Confidence Is Lacking In Assembly Biosciences, Inc. (NASDAQ:ASMB) As Shares Slide 27% - simplywall.st","headline":"Some Confidence Is Lacking In Assembly Biosciences, Inc. (NASDAQ:ASMB) As Shares Slide 27%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxQekM1Uko5M0tKaWJ1NXZOZVV6eUMxekFBVmRlZXgwVUQ5S3hGaVRRR2NCVERDbzVQZDc3TF9JWHNRN0lnWXYybjlkNzZ1Z0M2MkoxRlltRzVmYXl4N3lWS25KWUdpS2N0NFNyLTFoMzhJMGtDYzRkSlJJemRtNGVUY2RzQlhyMG5ZMXNsbXBvYkFaUTVoQXIyQms3VUlXZFNwYlpqSU9HcGUtWENCVlE?oc=5","date":"2026-01-14","type":"deal","source":"Fierce Biotech","summary":"JPM26: As lenacapavir momentum builds, Gilead eyes new deals from a 'position of strength' - Fierce Biotech","headline":"JPM26: As lenacapavir momentum builds, Gilead eyes new deals from a 'position of strength'","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgJBVV95cUxQbE9kSmQtYlZKNzJyV1R0MmRJc2ZZa0NWdmdLaDY5czhSdG5lc2VBNENYSkxYRzRtSE5saS05QUdBV0traWUxZmxIZEJLbldIZ0UyelFBT2JsOUdoRmdBUTVMOWkxdVRxTUN1Z1hQUGRFX2EyeGlxM0R4b3FtUzAzQzhaVWZtVnlhem1pOWtkd0FTaFR4SkVRY0VfdWN5czlpaGVIeEw2TmJ5c3RERmFRTE8yemY3LUJuN2h5cThRQWNJOWF1a2dKdXRYejB6VlNNVkVwaVA1Z2p5YllISEw3VGY4SXFmS3dEdzhSdjFwUjdMSjlWQU9qR3hzcnJ5elhNVjZORlBzdkg4eWR4Y3VOcG9xRDgxcjZ0Ul9WclFYSnJuT2hCcTlsTEhVUG9GZF9jZ1M2OG1lV1ZmRXBEZ1E?oc=5","date":"2026-01-09","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (EYPT), Viking Therapeutics (VKTX) and ANI Pharmaceuticals (ANIP) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (EYPT), Viking Therapeutics (VKTX) and ANI Pha","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-28","type":"deal","source":"Medical Dialogues","summary":"Gilead Sciences exercises option to license Assembly Biosciences Helicase-Primase Inhibitor programs for... - Medical Dialogues","headline":"Gilead Sciences exercises option to license Assembly Biosciences Helicase-Primase Inhibitor programs for...","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5IUXN2MXhSNDhBYlFTNHFYVklkLXlLeVAwOGY2aWo4bWFFdVJfSEtwN0t5SDZTU0pVeWpobHhxdmxvQmJoQzhGckxOb2hCV3hxRk1r?oc=5","date":"2025-12-23","type":"pipeline","source":"FirstWord Pharma","summary":"Gilead opts into Assembly's herpes duo - FirstWord Pharma","headline":"Gilead opts into Assembly's herpes duo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOdl93M3h0YXR0MnYzZzRFWTlyOGNiajloUW4zNVZSek8za1c0bXRmb0JiWTYyX3VpOGIwbHVLUGdyemp6T1FVc0trODlhdVVlNlBaMHpFTUZQNkFTbmtFeEVyWXRnOTg3Z20yVkdRTFd1RDc0R2dGcU5CMzhKQmVSSzhvUTZjbHJ1dTdLMmQ4cldJR09jMlp4SHB4UQ?oc=5","date":"2025-12-22","type":"deal","source":"Fierce Biotech","summary":"Gilead pays $35M to license pair of HSV assets from Assembly Bio pact - Fierce Biotech","headline":"Gilead pays $35M to license pair of HSV assets from Assembly Bio pact","sentiment":"neutral"},{"date":"2025-12-08","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxOZmhTemlRdko0YUY3T085WU1yVkxEVUllOTBvTmFuOWRLOGpDY0VSRUtydDdLTTdhQW03bXdlbVNEd2cxd2hBWEItMTNJWHhZblJrUjVPWDFRbnNxbzgzWG9Cbi1nZUp5NVV3TTg2LTFKdGRzRlpVRWRGd0RkTUNYS2dOenZtSHNXTElQaEg5ZDdZR0w0X3ZiSXBmdUk2QUlBSE51eXpyeW5Ga2xEX2NTd3U1VXJsMTV6eDRnWUVmNkxldXkxNmU2V3dkYjQ0dmY0WVVzMjJjRmhmQWw5MEVld2ZKTE03UzR6TkHSAe8BQVVfeXFMUEg3YUlRdUtlNXlBS0lVN0wyYkpkbTRVSnUzRGdsWjVsXzZKYWdaRUpxb2R5M3BuaFN3VmFFV0U4bzdRMkZHWFJDcGdRWEJGQUFoQ3h4Y1VHQVhZRjFVTjNuZ2FVTDU3RHh1RTJBVmxCQUwwUl9VVDZFQnVCcTB1TnZSUmxDNWJ3T1lPbnAtOExGUEJiYlloamIxenI2dnRIYUdIbHlRQm5XOFhZOHA3NWNYUnhqTXFxTW1melpwdVBnUk04bUxNQkZmS0pzRW9ONU1BNXRuQTRSOEJubC1xVkk1UzRld3FaT1NQWS1NM0U?oc=5","date":"2025-12-02","type":"pipeline","source":"simplywall.st","summary":"Companies Like Assembly Biosciences (NASDAQ:ASMB) Can Afford To Invest In Growth - simplywall.st","headline":"Companies Like Assembly Biosciences (NASDAQ:ASMB) Can Afford To Invest In Growth","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNN0FQcjdnYjl6Sm01aTV2Y1BWSFdPdnBGWVdxdWF2WUZwbllpVE8yOTVJLVo3LWNwQXdueWRrVFdBdklxRTlRQXE3N1RLSC1jazhUY05ZVXRkbE5hX2hZd0ljSE9RMWJtcE1IdGJzZ2FndzBULWUwMnFWRlJNR2xCSWJpVHZIZlZXd2tGd3VPeDY5T0xZc0ZvaEZHNjBRS1o3UUNOczgtT2I4WUNl?oc=5","date":"2025-11-14","type":"pipeline","source":"BioWorld News","summary":"Invivyd, Emergent and Armata drive infectious disease stock recovery - BioWorld News","headline":"Invivyd, Emergent and Armata drive infectious disease stock recovery","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPQk8tT2ZzTmQ0QklrQllaSVAxaDY3NC12TkpRWGVoQWhmSkxBTzZLSWlnaEdEQjUyUzdOUUlBYk9Gc3dKX3puQ1pVWkdGT3VMUWwyOGt6ZWVWbzlsNHprT3NPTTRGNVRQT0JWRV92bDZmcjU2ekZELXZEdFh5cXg5RWhDaTM3bmxtSnByV1VB?oc=5","date":"2025-11-10","type":"pipeline","source":"Yahoo Finance","summary":"US Live Biotherapeutics Market Research 2025, Competitive Analysis of Arrant Bio, 4D Pharma, Cerbios, Biose, Assembly Biosciences, Wacker Chemie, Quay Pharmaceuticals, NIZO, Lonza, Inpac Probiotics - ","headline":"US Live Biotherapeutics Market Research 2025, Competitive Analysis of Arrant Bio, 4D Pharma, Cerbios, Biose, Assembly Bi","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":72303000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":72303000,"period":"2025-12-31"},{"value":28520000,"period":"2024-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":64813000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-6122000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":257590000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}